You might know you need to conduct drug metabolism and pharmacokinetic (DMPK) analysis, but which tests are right for your project? And are you doing them at the right time? When building your preclinical strategy, these questions matter—and that’s true now more than ever, as new drug classes and targets emerge.
September 30, 2020
- The Importance of Conducting PDX Oncology Studies in a Humanized Immune System
- Leveraging Flow Cytometry to Drive Better Patient Outcomes in Hematologic Malignancy Clinical Trials
- The Importance of Incorporating Metabolomic and Proteomic Screening in Preclinical Oncology Studies
- Challenges in Radiopharmaceutical Development for Oncology Therapies
- Emerging Trends in Radiopharmaceuticals
The Importance of Conducting PDX Oncology Studies in a Humanized Immune System
Preclinical oncology studies are a critical step in developing effective cancer therapies. Patient-derived xenograft (PDX) models have become a ...
Leveraging Flow Cytometry to Drive Better Patient Outcomes in Hematologic Malignancy Clinical Trials
In oncology, evaluating treatment efficacy often relies on standardized criteria such as RECIST (Response Evaluation Criteria in Solid Tumors), which ...
The Importance of Incorporating Metabolomic and Proteomic Screening in Preclinical Oncology Studies
The evolving complexity of oncology drug development demands an equally sophisticated approach to understanding the tumor microenvironment and its ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
